(1) Build a platform to establish the viral determinants that can modulate inflammation and/or cell death. (2) To develop novel approaches to counteract inflammation as a possible treatment.
The reason why some people develop exacerbated inflammation leading to the severity of the disease remains unknown. Having a deeper understanding of the interaction between SARS-Cov-2 and the immune systems of host organisms will help to understand the development and persistence of inflammation in the lungs, and may reduce the risk of lung inflammation caused by SARS-Cov-2.
Short term: Generation of a platform to carry out initial screening of possible anti-inflammatory treatments in a quick and effective manner and to identify therapeutic targets involved in inflammation and/or cell death against which to design new drugs.
Long term: Possible new therapeutic treatment (using microRNA); and repositioning of drugs with anti-inflammatory activity.
Principal Investigator: María Montoya (CIB)